Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
New device harnesses microwave flow reaction to convert biomass into useful sugars
Researchers at Kyushu University have developed a device that combines a catalyst and microwave flow reaction to efficiently ...
Hippocratic AI secures $141m in Series B funding
Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...
Investor's Business Daily on MSN15h
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals
Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
marketinference21h
Catalyst Pharmaceuticals Settles Patent Dispute
Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
Investor's Business Daily on MSN15h
Alkermes Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Rating on Friday, rising from 69 to 74. Please watch the video at Investors.com - How To Find Game-Changing Stocks This proprietary rating tracks technical performance by showing how a stock's price ...
Dow tumbles nearly 700 points Friday as strong jobs report casts doubt over Fed's rate-cut path
The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...
Crinetics falls after mid-stage trial data adrenal disorder therapy
Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.